Omnigene Medical Technologies
  • We innovate for better Health

    A multidisciplinary approach to solve clinical needs

    Our expert team enables access to accurate, sensitive and innovative methods supporting research and diagnostics of clinical relevance.           

    or send us an email on scientific.support@genemt.com

  • We invest in research

    Research projects to optimise technologies and develop & validate test prototypes

    ​Our research scientists have ample experience in optimising molecular technologies, bead-based multiplex assay development, developing quality control material.  Areas include oncology, neuroscience and research on SARS-CoV-2 (COVID-19) induced immune response. 

  • We work with Partners

    Recognised by International Partners

    Fully supported by Luminex Corporation, ThermoFisher, NMI-TT, miRXES  

Products & Services

We are excited to announce our success to innovate test-based programs utilising the CE-IVD Dysbiosis test for inflammatory bowel disease (GA-map).  In addition, we licensed-in intellectual property and secured freedom-to-operate in Europe for the first multiplex assay to classify breast cancer.   Ongoing projects include the M3 Profiler aiming to characterise exosomes in cancer patients,  and the upcoming launch of Lifestyle medicine clinics in collaboration with our local and international partners.  We have aligned with European associations and the press releases shall be communicated in the next few months.


Join us in our mission:

  • An RUO molecular classification of breast cancer is now approved for sale in Europe.
  • Prevention of colorectal cancer is also high on our agenda.  Learn more about the Gut restore program as an actionable tool to reduce intestinal inflammation. 
  • Our R&D embarked on setting up sensitive techniques to measure biomarkers in blood-derived exosomes.
  • Our professional team is seeking partnerships to enhance market entry and develop new products. 
  • Our commercial team is providing high quality reagents for research institutions, including cutting edge technologies and services.


Join Us

Research Projects & Innovations

M3 PROFILER

To synergise the advantages of microfluidics, and multiplex bead based assays, to measure biomarkers in blood-derived exosomes.

iMPACT

Innovative molecular profiling assays to classify tumours.  We developed multiplex assays for academic research and clinical laboratories.

Gut Restore Program

A 6-month program to restore intestinal function. Includes microbiota and lipid profile test.  Now available from Saint James Hospitals (Malta).  

Dysbiosis CE-IVD

Omnigene obtained technology transfer of the GA-map dysbiosis test.  Various programs are under development to offer Lifestyle interventions, targeting PCOS, auto-immunity, sports performance, corporate wellness, amongst others.

Previous Projects

Omnigene was involved in various research projects.  

A molecular test was developed that measures COVID-19 (SARS-CoV-2) immune response for vaccine surveillance.

BOOKIND. 

A companion diagnostic product that predicts use of specific therapeutics in Epilepsy.

Who Are We ?

About Us

The executive team brings together a wealth of experience in health management, quality standards, commercial licensing, scientific excellence and product development & innovation.  Together with the scientific team the company invested in research projects to enable innovations and secured international reputation with more than 10 partners globally.

  • innovative cancer tests
  • accurate & sensitive measurements
  • enable use of low input, low quality precious patient material
  • clinical relevant solutions in oncology 
  • competitive prices

10+

international partners

1000+

Hours of Research & Innovation

10+

Years Experience

Investment is the KEY to innovation

Innovation is the KEY to better Health

Help us make an impact - Follow us

What our partners have to say

Testimonial